Centre for Women's Health, Gender and Society, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia,
Breast Cancer Res Treat. 2014 Jan;143(2):367-72. doi: 10.1007/s10549-013-2794-5. Epub 2013 Dec 11.
There is a lack of evidence regarding the optimal age at which to cease mammographic screening for breast cancer. This ecological study compared Australian state and territory level screening participation rates and cancer outcomes from 1996 to 2005 to identify the extent to which screening women aged 70-74 results in smaller, earlier stage breast cancers. With each 10 % absolute increase in screening participation, there was no significant difference in cancer incidence, but the incidence of large cancers was 8 % lower (IRR = 0.92, 95 % CI 0.90-0.94, p < 0.001); there was some evidence of reduced nodal involvement at diagnosis (IRR 0.97, 95 % CI 0.95-0.99, p = 0.004) but this estimate was sensitive to assumptions regarding missing data. Increased mammographic screening of women aged 70-74 years reduces the incidence of large (>15 mm) cancers-and possibly cancers with nodal involvement-without a concomitant increase in overall cancer incidence.
关于何时停止乳腺癌的乳房 X 光筛检的最佳年龄,目前仍缺乏相关证据。本项生态学研究对比了澳大利亚各州和地区 1996 年至 2005 年的筛检参与率和癌症结果,以确定对 70-74 岁女性进行筛检在多大程度上可发现更小、更早阶段的乳腺癌。筛检参与率每增加 10 %,癌症发病率并无显著差异,但大肿瘤的发病率降低了 8 %(IRR = 0.92,95 % CI 0.90-0.94,p < 0.001);诊断时淋巴结受累的情况也有一定程度的减少(IRR 0.97,95 % CI 0.95-0.99,p = 0.004),但这一估计结果对缺失数据的假设较为敏感。对 70-74 岁女性进行更多的乳房 X 光筛检可降低大肿瘤(>15 毫米)的发病率,以及可能具有淋巴结受累的肿瘤的发病率,而不会同时增加总体癌症发病率。